Catalyst
Slingshot members are tracking this event:
Merrimack Pharmaceuticals (MACK) expecting data and appropriate Phase 2 dosage from Phase 1 cancer study on MM-310 in 2018 - Discontinued
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MACK |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 04, 2019
Occurred Source:
http://investors.merrimack.com/news-releases/news-release-details/merrimack-discontinues-development-mm-310
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1, Mm-310, Solid-tumor Cancers, Discontinued, Discontinuation
